NASDAQ:YMTX - Yumanity Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $35.00
  • Forecasted Upside: 101.15 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$17.40
▼ -0.02 (-0.11%)
Get New Yumanity Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for YMTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for YMTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$35.00
▲ +101.15% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Yumanity Therapeutics in the last 3 months. The average price target is $35.00, with a high forecast of $35.00 and a low forecast of $35.00. The average price target represents a 101.15% upside from the last price of $17.40.
Buy
The current consensus among 2 investment analysts is to buy stock in Yumanity Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/30/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/1/2021Jefferies Financial GroupInitiated CoverageBuy$35.00N/A
i
12/23/2020Piper SandlerReiterated RatingOverweightN/A
i
(Data available from 4/22/2016 forward)
Yumanity Therapeutics logo
Yumanity Therapeutics Inc. discovers and develops disease-modifying therapies for neurodegenerative diseases. It focuses on discovering disease-modifying therapies for patients with Parkinson's, amyotrophic lateral sclerosis, and Alzheimer's diseases. The company concentrates on reversing the cellular phenotypes and disease pathologies caused by protein misfolding. Yumanity Therapeutics Inc. has a strategic research collaboration and license agreement with Merck. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $17.40
$16.66
$17.47

50 Day Range

MA: N/A

52 Week Range

Now: $17.40

Volume

11,614 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Yumanity Therapeutics?

The following equities research analysts have issued research reports on Yumanity Therapeutics in the last twelve months: Jefferies Financial Group Inc., Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for YMTX.

What is the current price target for Yumanity Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Yumanity Therapeutics in the last year. Their average twelve-month price target is $35.00, suggesting a possible upside of 101.1%. Jefferies Financial Group Inc. has the highest price target set, predicting YMTX will reach $35.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $35.00 for Yumanity Therapeutics in the next year.
View the latest price targets for YMTX.

What is the current consensus analyst rating for Yumanity Therapeutics?

Yumanity Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe YMTX will outperform the market and that investors should add to their positions of Yumanity Therapeutics.
View the latest ratings for YMTX.

What other companies compete with Yumanity Therapeutics?

How do I contact Yumanity Therapeutics' investor relations team?

The company's listed phone number is (617) 225-0096. The official website for Yumanity Therapeutics is www.yumanity.com.